Andrew S. Fein
Stock Analyst at HC Wainwright & Co.
(4.81)
# 86
Out of 5,090 analysts
31
Total ratings
85.19%
Success rate
28.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew S. Fein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FULC Fulcrum Therapeutics | Maintains: Buy | $12 → $18 | $8.88 | +102.82% | 2 | Nov 24, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $568 → $620 | $591.06 | +4.90% | 3 | Nov 21, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Neutral | $12 → $9 | $6.78 | +32.74% | 3 | Nov 11, 2025 | |
| PRTA Prothena Corporation | Maintains: Buy | $20 → $30 | $11.30 | +165.49% | 3 | Nov 7, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $95 → $190 | $93.90 | +102.35% | 3 | Nov 6, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $70 → $84 | $66.56 | +26.20% | 2 | Nov 5, 2025 | |
| LQDA Liquidia | Maintains: Buy | $35 → $50 | $33.97 | +47.19% | 2 | Nov 4, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $500 → $525 | $485.21 | +8.20% | 1 | Oct 30, 2025 | |
| DBVT DBV Technologies | Maintains: Buy | $16 → $20 | $13.09 | +52.79% | 1 | Oct 29, 2025 | |
| AKRO Akero Therapeutics | Downgrades: Neutral | $72 → $54 | $54.59 | -1.07% | 2 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $7.44 | $27.21 | -72.66% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $12 | $0.67 | +1,698.56% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $22 | $7.56 | +191.01% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $8 | $6.38 | +25.49% | 2 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $240 | $205.04 | +17.05% | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $18 | $12.62 | +42.69% | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $25 | $8.41 | +197.27% | 1 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $478 | $457.26 | +4.54% | 1 | Aug 5, 2025 |
Fulcrum Therapeutics
Nov 24, 2025
Maintains: Buy
Price Target: $12 → $18
Current: $8.88
Upside: +102.82%
Madrigal Pharmaceuticals
Nov 21, 2025
Maintains: Buy
Price Target: $568 → $620
Current: $591.06
Upside: +4.90%
Arcturus Therapeutics Holdings
Nov 11, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $6.78
Upside: +32.74%
Prothena Corporation
Nov 7, 2025
Maintains: Buy
Price Target: $20 → $30
Current: $11.30
Upside: +165.49%
Palvella Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $95 → $190
Current: $93.90
Upside: +102.35%
Kymera Therapeutics
Nov 5, 2025
Maintains: Buy
Price Target: $70 → $84
Current: $66.56
Upside: +26.20%
Liquidia
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $50
Current: $33.97
Upside: +47.19%
United Therapeutics
Oct 30, 2025
Maintains: Buy
Price Target: $500 → $525
Current: $485.21
Upside: +8.20%
DBV Technologies
Oct 29, 2025
Maintains: Buy
Price Target: $16 → $20
Current: $13.09
Upside: +52.79%
Akero Therapeutics
Oct 10, 2025
Downgrades: Neutral
Price Target: $72 → $54
Current: $54.59
Upside: -1.07%
Sep 4, 2025
Assumes: Neutral
Price Target: $7.44
Current: $27.21
Upside: -72.66%
Sep 4, 2025
Assumes: Buy
Price Target: $12
Current: $0.67
Upside: +1,698.56%
Sep 3, 2025
Reiterates: Buy
Price Target: $22
Current: $7.56
Upside: +191.01%
Sep 3, 2025
Maintains: Buy
Price Target: $5 → $8
Current: $6.38
Upside: +25.49%
Aug 13, 2025
Maintains: Buy
Price Target: $120 → $240
Current: $205.04
Upside: +17.05%
Aug 7, 2025
Maintains: Buy
Price Target: $24 → $18
Current: $12.62
Upside: +42.69%
Aug 6, 2025
Maintains: Buy
Price Target: $36 → $25
Current: $8.41
Upside: +197.27%
Aug 5, 2025
Maintains: Buy
Price Target: $550 → $478
Current: $457.26
Upside: +4.54%